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Evidence of relative eﬀectiveness of local treatments for hepatocellular carcinoma (HCC) is scanty. We investigated, in a
retrospective cohort study, whether surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and
transarterial embolization with (TACE) or without (TAE) chemotherapy resulted in diﬀerent survival in clinical practice. All
patients ﬁrst diagnosed with HCC and treated with any locoregional therapy from 1998 to 2002 in twelve Italian hospitals were
eligible. Overall survival (OS) was the unique endpoint. Three main comparisons were planned: RFA versus PEI, surgical resection
versus RFA/PEI (combined), TACE/TAE versus RFA/PEI (combined). Propensity score method was used to minimize bias related
to non random treatment assignment. Overall 425 subjects were analyzed, with 385 (91%) deaths after a median followup of 7.7
years. OS did not signiﬁcantly diﬀer between RFA and PEI (HR 1.11, 95% CI 0.79–1.57), between surgery and RFA/PEI (HR 0.95,
95% CI 0.64–1.41) and between TACE/TAE and RFA/PEI (HR 0.88, 95% CI 0.66–1.17). 5-year OS probabilities were 0.14 for RFA,
0.18 for PEI, 0.27 for surgery, and 0.15 for TACE/TAE. No locoregional treatment for HCC was found to be more eﬀective than the
comparator. Adequately powered randomized clinical trials are still needed to deﬁnitely assess relative eﬀectiveness of locoregional
HCC treatment.
1.Introduction
Locoregional treatments are the mainstay of treatment of
early stage hepatocellular carcinoma (HCC) [1–3]. Surgical
resection should be particularly considered for patients with
solitary tumours and well-preserved liver function. Trans-
arterial embolization with (TACE) or without (TAE) chemo-
therapy is recommended for intermediate stage HCC pa-2 The Scientiﬁc World Journal
tients who are ineligible for surgery or percutaneous ablation
[1–3]. However evidence of relative eﬀectiveness on survival
of local treatments for hepatocellular carcinoma (HCC) is
scanty due to the paucity of clinical trials and shortness of
followup.
A meta-analysis [4] that compared surgery versus abla-
tive treatments in the subgroup of tumors >3cm found
a survival beneﬁt of surgery, but concluded that level of
evidence was low and that further RCT were needed.
Twometa-analyses[5,6],comparedradiofrequencyabla-
tion (RFA) with PEI, and found a slight survival improve-
mentwithRFAoverPEI,butrelieduponfewsmalltrialswith
a short followup period and a limited number of events.
Three meta-analyses [7–9] assessed the eﬃcacy of
TACE/TAE versus supportive care, but ended up with
contrasting results. Geschwind et al. failed to show a survival
advantage versus supportive care alone and emphasised the
poor quality of published trials [7]. Camm` a et al. claimed
that both TACE/TAE signiﬁcantly reduced overall 2-year
mortality, but the magnitude of beneﬁt was relatively small
[8]. Llovet and Bruix found that arterial embolization
improved 2-year survival versus control, and this beneﬁt was
signiﬁcant for TACE but not for TAE [9].
In general, these studies were conducted in specialized
reference centers in well-selected patients. In this observa-
tional cohort study we assessed the relative eﬀectiveness on
long-term survival of locoregional treatments for HCC in
real-world patients.
2. Patientsand Methods
2.1. Study Subjects. T h es t u d yh a dar e t r o s p e c t i v ec o h o r t
design. All patients ﬁrst diagnosed with HCC (ICD-9 155.0)
and treated with any locoregional therapy from 1998 to
2002 in public hospitals of Campania, southern Italy, were
potentiallyeligible.Potentialpatientswereretrievedfromthe
Discharge Information System of the Regional Health Ser-
vice; eligibility criteria were subsequently checked by perus-
ing clinical records. Child-Pugh score C, presence of portal
vein thrombosis, massive tumour morphology and liver
involvement greater than 50% were exclusion criteria. Time
interval was chosen “a priori” to allow an adequate followup.
Thestudyprotocolwasapprovedbytheethiccommittees
of all the participating Institutions.
2.2. Endpoint and Covariates. Overall survival (OS) was the
unique outcome measure and was deﬁned as the time from
the date of the ﬁrst local intervention until death for any
cause or until date of last followup. Date of death was ascer-
tainedbytheadministrativeregistryoﬃcesofpatients’towns
of residence.
Baseline demographic, clinical, and tumour-related vari-
ables were derived from clinical records. The CLIP prog-
nostic score [10, 11], used for statistical adjustment, was
calculated “a posteriori” from information reported in clini-
cal records. Performance status was very rarely reported so
that the Barcelona Clinic Liver Cancer [3] staging could not
be assessed.
2.3. Statistical Analysis. Three main comparisons were plan-
ned, RFA versus PEI, surgery versus RFA or PEI, TACE/TAE
versus RFA or PEI.
To minimize biases related to nonrandom assignment we
used the propensity score method [12–14], where the rela-
tionship between treatment and survival is adjusted for pa-
tient’s likelihood of receiving that therapy given his/her pro-
gnostic proﬁle.
For each comparison the primary multivariable analysis
was performed by a Cox proportional hazard model with
compared treatments and propensity score as covariates,
stratiﬁed by the number of missing values in the CLIP score
components. Propensity score was estimated for each comz
parison by a logistic regression model that included, as cov-
ariates, age, sex, CLIP prognostic score, and number of miss-
ing components of the CLIP score [15]. Only subjects with
overlapping values of propensity score were analysed for
each main comparison. Proportional hazard assumption was
checked by graphical inspection [16].
As a sensitivity analysis, further statistical models were
performed to assess the consistency of results [17–20]: (i)
modelling propensity score with cubic regression splines in
order to obviate the need for assuming a linear eﬀect [17],
(ii) stratifying the model by subclasses deﬁned by propen-
sity score quintiles [18], (iii) weighting each subject by the
inverse of the individual probability of receiving the treat-
ment assumed, estimating variance via the empirical sand-
wich method [19], and (iv) substituting CLIP score in the
Cox model with its components [20].
Unadjusted cumulative survival curves were depicted by
Kaplan-Meier (K-M) method and compared by the Mantel-
Haenszel test (MH) and Peto and Peto modiﬁcation of the
Wilcoxon rank sum test (WPP). The two tests give diﬀerent
weights to events, the second one giving more weight to earl-
ier events.
Since guidelines [1, 2] suggest that treatments could have
diﬀerent eﬀects in particular subgroups of subjects, for each
comparison we repeated analyses in predeﬁned subgroups of
subjects.
All analyses were performed with R software, version
2.9.1 (Development Core Team. R: A Language and Environ-
ment for Statistical Computing. R Foundation for Statistical
Computing. 2009).
3. Results
Overall 441 HCC patients discharged from January 1998 and
December 2002 were eligible. Sixteen cases were excluded
because of lack of any follow-up information, thus the ﬁnal
study sample involved 425 subjects. Baseline characteristics
of the 425 patients are reported in Table 1. PEI was the most
common treatment (60%) followed by TACE/TAE (19%),
w h i l es u r g i c a lr e s e c t i o na n dR F Aw e r ep e r f o r m e di nf e w e r
subjects. Three patients received at the same time both PEI
a n dR F Aa n dw e r ee x c l u d e do n l yf r o mt h ec o m p a r i s o no f
PEIversusRFA;eightpatientsreceivedotherlocaltreatments
(laser therapy) and were excluded from all comparisons. On
the whole, prognostic factors did not diﬀer a lot among
treatments, although seemingly surgery was performed inThe Scientiﬁc World Journal 3
Table 1: Baseline characteristics of the study patients by treatment. Data are reported as absolute numbers (percentages), but for age and
AFP.
Variable Total
(N = 425)
Surgery
(N = 34)
PEI◦
(N = 256)
RFA◦
(N = 50)
TAE/TACE
(N = 80)
Other
∧
(N = 8)
Year of diagnosis
1998 33 (8%) 4 (12%) 23 (9%) 2 (4%) 4 (5%) 0 (0%)
1999 83 (20%) 5 (15%) 55 (21%) 9 (18%) 14 (18%) 0 (0%)
2000 106 (25%) 12 (35%) 59 (23%) 9 (18%) 26 (32%) 1 (13%)
2001 112 (26%) 7 (21%) 68 (27%) 16 (32%) 21 (26%) 1 (13%)
2002 91 (21%) 6 (18%) 51 (20%) 14 (28%) 15 (19%) 6 (75%)
Male gender 327 (77%) 30 (88%) 188 (73%) 40 (80%) 65 (81%) 7 (88%)
Age yrs, mean (SD) 67 (8) 62 (7) 68 (7) 67 (8) 64 (8) 68 (7)
Diagnostic assessment
Histology 195 (46%) 23 (68%) 125 (49%) 13 (26%) 32 (40%) 3 (38%)
Instrumental + AFP > 200 51 (12%) 3 (9%) 28 (11%) 9 (18%) 12 (15%) 0 (0%)
Instrumental only 179 (42%) 8 (24%) 103 (40%) 28 (56%) 36 (45%) 5 (63%)
Instrumental appraisal
Ultrasonography 187 (44%) 11 (32%) 123 (48%) 21 (42%) 27 (34%) 6 (75%)
NMR 13 (3%) 4 (12%) 4 (2%) 5 (10%) 0 (0%) 0 (0%)
CT 178 (42%) 14 (41%) 96 (38%) 20 (40%) 48 (60%) 2 (25%)
Missing 47 (11%) 5 (15%) 33 (13%) 4 (8%) 5 (6%) 0 (0%)
Underlying liver disease
Liver cirrhosis 414 (97%) 32 (94%) 250 (98%) 49 (98%) 78 (98%) 8 (100%)
Chronic Hepatitis 11 (3%) 2 (6%) 6 (2%) 1 (2%) 2 (2%) 0 (0%)
Etiology
Viral 366 (86%) 32 (94%) 214 (83%) 46 (92%) 71 (89%) 6 (75%)
Nonviral 10 (2%) 0 (0%) 8 (3%) 0 (0%) 2 (2%) 0 (0%)
Missing 49 (12%) 2 (6%) 34 (13%) 4 (8%) 7 (9%) 2 (25%)
Viral etiology
HCV 324 (76%) 24 (71%) 197 (77%) 43 (86%) 56 (70%) 7 (88%)
HBV 59 (14%) 9 (26%) 21 (8%) 11 (22%) 18 (22%) 1 (13%)
Child-Pugh score
A 200 (47%) 22 (65%) 105 (41%) 26 (52%) 42 (52%) 7 (88%)
B 137 (32%) 8 (24%) 79 (31%) 20 (40%) 31 (39%) 0 (0%)
Missing 88 (21%) 4 (12%) 72 (28%) 4 (8%) 7 (9%) 1 (12%)
AFP mg/dl, median (IQ range) 27 (7–156) 12 (3–146) 28 (8–127) 34 (9–183) 31 (7–334) 14 (5–27)
Number of nodules
<4 305 (72%) 25 (74%) 189 (74%) 38 (76%) 49 (61%) 5 (62%)
≥4 12 (3%) 0 (0%) 3 (1%) 1 (2%) 8 (10%) 0 (0%)
Missing 108 (25%) 9 (26%) 64 (25%) 11 (22%) 23 (29%) 3 (38%)
Tumour size (cm)
≤3 207 (49%) 13 (38%) 143 (56%) 24 (48%) 23 (29%) 5 (62%)
3–5 90 (21%) 9 (26%) 43 (17%) 11 (22%) 28 (35%) 0 (0%)
>5 39 (9%) 4 (12%) 12 (5%) 7 (14%) 15 (19%) 1 (12%)
Missing 89 (21%) 8 (24%) 58 (23%) 8 (16%) 14 (18%) 2 (25%)
Tumour morphology
Single nodule 204 (48%) 18 (53%) 132 (52%) 23 (46%) 26 (32%) 5 (62%)
Multiple nodules 175 (41%) 10 (29%) 93 (36%) 24 (48%) 48 (60%) 3 (38%)
Missing 46 (11%) 6 (18%) 31 (12%) 3 (6%) 6 (8%) 0 (0%)4 The Scientiﬁc World Journal
Table 1: Continued.
Variable Total
(N = 425)
Surgery
(N = 34)
PEI◦
(N = 256)
RFA◦
(N = 50)
TAE/TACE
(N = 80)
Other
∧
(N = 8)
CLIP score
0 76 (18%) 9 (26%) 43 (17%) 10 (20%) 12 (15%) 2 (25%)
1 111 (26%) 10 (29%) 65 (25%) 13 (26%) 23 (29%) 1 (12%)
2 59 (14%) 3 (9%) 29 (11%) 9 (18%) 19 (24%) 1 (12%)
3 14 (3%) 0 (0%) 6 (2%) 3 (6%) 5 (6%) 0 (0%)
>3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Missing 165 (39%) 12 (35%) 113 (44%) 15 (30%) 21 (26%) 4 (50%)
◦Including three subjects who received both RFA and PEI;
∧Including 8 laser therapy; PEI: percutaneous ethanol injection, RFA: radiofrequency ablation,
TACE/TAE transarterial embolization with (TACE) or without (TAE) chemotherapy, AFP: alphafetoprotein, NMR nuclear magnetic resonance.
0123456789
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Figure 1: Kaplan-Meier cumulative survival curves for the study
treatments.
patients with a more favourable prognostic proﬁle, and
TACE/TAEinpatientswithmoreseveredisease.Overall,after
a median follow-up time of 7.7 years, 385 (91%) deaths were
registered. Observed cumulative survival curves for all study
treatments are depicted in Figure 1.
In Table 2 we reported results of the three multivariable
primary analyses.Nosigniﬁcant diﬀerencein overallsurvival
was found for any of the three planned comparisons.
Hazard ratio (HR) of RFA versus PEI was equal to 1.11
(95% C.I. 0.79 to 1.57, P = 0.53). Estimated probabilities to
be alive at 5 years were equal to 0.14 (95% CI 0.07 to 0.27)
and 0.18 (95% CI 0.14 to 0.23) for RFA and PEI, respectively.
At the univariate analysis, both MH test (P = 0.36) and WPP
test (P = 0.14) were not statistically signiﬁcant (Figure 1).
HR of surgery versus the two percutaneous ablation
therapies combined was equal to 0.95 (95% C.I. 0.64 to 1.41,
Table 2: Eﬀectiveness of locoregional treatment on overall survival
in Cox proportional hazard model adjusted by propensity score.
Model HR (95% CI) P
RFA versus PEI
(n = 47+ 239) 1.11 (0.79–1.57) 0.53
Surgery versus RFA/PEI
(n = 34+ 255) 0.95 (0.64–1.41) 0.79
TAE/TACE versus RFA/PEI
(n = 80+ 287) 0.88 (0.66–1.17) 0.38
PEI: percutaneous ethanol injection, RFA radiofrequency ablation,
TACE/TAE: transarterial embolization with (TACE) or without (TAE)
chemotherapy.
P = 0.79). Estimated probabilities to be alive at 5 years were
equal to 0.27 (95% CI 0.16 to 0.46) and 0.17 (95% CI 0.13 to
0.22) for surgery and RFA/PEI, respectively. At the univariate
analysis both MH (P = 0.52) and WPP test (P = 0.94) were
not statistically signiﬁcant (Figure 1).
HR of TACE/TAE versus the two percutaneous ablation
therapies combined was equal to 0.88 (95% C.I. 0.66 to 1.17,
P = 0.38). Estimated probabilities to be alive at 5 years
were equal to 0.15 (95% CI 0.10 to 0.24) and 0.17 (95%
CI 0.13 to 0.22) for TACE/TAE and RFA/PEI, respectively.
At the univariate analysis MH test did not reveal diﬀerences
between arms (P = 0.44) while WPP test (P = 0.03) was
statisticallysigniﬁcant(Figure 1),thushighlightinganearlier
prognostic advantage for RFA/PEI that later disappeared.
Superimposableresultswerefoundforallcomparisonsat
sensitivity analyses, where other adjustment modalities were
applied (Table 3).
Results of univariate analyses in predeﬁned subgroups of
subjects for the three comparisons are reported in Figure 2.
For every comparison, results in the study subgroups were
similar to the overall analyses without any evidence of hete
rogeneity.
4. Discussion
This observational study in a clinical practice setting did not
ﬁnd survival diﬀerences between local treatments in any of
the study comparisons. Clearly, robust evidence of treatment
eﬃcacy may only result from adequately powered rando-The Scientiﬁc World Journal 5
Table 3: Eﬀectiveness of locoregional treatment on overall survival in Cox proportional hazard model adjusted by propensity score.
Sensitivity analysis.
Model HR (95% CI) P
RFA versus PEI (n = 47+ 253)
Adjustment by propensity score (n = 47+ 239)
Linear 1.11 (0.79–1.57) 0.53
Cubic spline 1.09 (0.77–1.54) 0.63
Stratiﬁed (quintiles) 1.11 (0.78–1.58) 0.56
Inverse probability weighting 1.13 (0.82–1.57) 0.46
Adjustment by prognostic covariates (n = 47+253) 1.21 (0.87–1.71) 0.25
Surgery versus RFA/PEI (n = 34+303)
Adjustment by propensity score (n = 34+ 255)
Linear 0.95 (0.64–1.41) 0.79
Cubic spline 0.95 (0.64–1.41) 0.81
Stratiﬁed (quintiles) 0.95 (0.61–1.48) 0.82
Inverse probability weighting 0.80 (0.52–1.24) 0.32
Adjustment by prognostic covariates (n = 34+303) 0.96 (0.64–1.42) 0.82
TAE/TACE versus RFA/PEI (n = 80 +303)
Adjustment by propensity score (n = 80+ 287)
Linear 0.88 (0.66–1.17) 0.38
Cubic spline 0.89 (0.67–1.18) 0.41
Stratiﬁed (quintiles) 0.86 (0.65–1.15) 0.32
Inverse probability weighting 0.98 (0.73–1.32) 0.90
Adjustment by prognostic covariates (n = 80+303) 0.83 (0.63–1.10) 0.20
PEI: percutaneous ethanol injection, RFA: radiofrequency ablation, TACE/TAE: transarterial embolization with (TACE) or without (TAE) chemotherapy.
0.3 0.7 1 1.5 2.5 3.5
Child-Pugh A
Child-Pugh B
Single nodule
Multiple nodules
Overall
0.3 0.7 1 1.5 2.5 3.5 0.3 0.7 1 1.5 2.5 3.5
Hazard ratio Hazard ratio Hazard ratio
RFA better PEI better Surgery better RFA/PEI better TACE/TAE better RFA/PEI better
RFA versus PEI Surgery versus PEI/RFA TAE/TACE versus PEI/RFA 
AFP <400
AFP ≥400
Tumor size ≥3
Tumor size >3
Figure 2: Univariate comparisons of RFA versus PEI (left panel), surgical resection versus RFA/PEI (middle panel) and TACE/TAE versus
RFA/PEI (right panel) within major patient subgroups. The area of each square is proportional to the size of the subgroup; horizontal lines
depict 95% conﬁdence intervals of the hazard ratio estimates.
mized trials and observational studies may be ﬂawed by sev-
eralshortcomings.However,ourﬁndingsaddanotablepiece
of information to the literature of locoregional treatments
for HCC, where only small clinical trials, if any, are available
and are usually performed in specialized reference centers on
well-selected patients.
Inthisstudyweaddressedthepotentialbiasesofobserva-
tionalstudiesinseveralways.First,wepursuedapopulation-
based approach, identifying the reservoir of potentially
eligible patients from an independent source (the Discharge
Information System of the Campania Regional Health Ser-
vice), thus reducing the risk of selection bias. In addition we6 The Scientiﬁc World Journal
chose survival as the unique endpoint of the study, as rec-
ommended when eﬀectiveness between therapies is assess-
ed [1, 2]. To remove the ascertainment bias, the date of death
was independently derived from the administrative death
registries. We were unable to assess the outcome only in 16
subjects because of migration or mistakes in residence infor-
mation. Finally, we counteracted indication bias (i.e., pa-
tients’ selection for diﬀerent therapies) by adjusting com-
parisons for propensity score [12–14], (i.e., the probability
of receiving a given therapy conditionally on the patient’s
individual prognostic proﬁle).
A major strength of our study is the length of followup
with a large number of deaths observed (91% of the whole
sample), that allowed a complete picture of the survival ex-
perience of the study cohort. To our knowledge, our cohort
is the largest reported in the literature for this kind of study,
after the one of Arii et al. who used a population-based
approach starting from a nationwide survey in Japan [21].
Furthermore, from a methodological viewpoint, we assess-
ed whether results persisted under possible violations of the
statistical assumptions, by repeating the analyses with several
adjustment modalities. The consistency of results across dif-
ferent models reinforces their validity, although some resid-
ual confounding could still be present, due to unknown co-
variates not included in the models [22, 23].
We adjusted for missing information in multivariable
analyses, but we acknowledge that missing data might
partially aﬀect our ﬁndings. Furthermore we only assessed
ﬁrst-line local treatments, since information on successive
treatments was largely unreliable.
The major and unexpected ﬁnding of our results was
the lack of signiﬁcant diﬀerences even in univariate analyses,
where we expected survival diﬀerences at least as a conse-
quence of indication bias. Actually patients’ baseline chara-
cteristics overlapped substantially among treatments, despite
the careful selection recommended by the international
guidelines [1, 2]. Although this might be partly explained
by the fact that our cohort was antecedent to guidelines, an
alternative explanation is that the choice of local treatment
was rather driven by clinicians’ preferences or availability of
skills.
Although our results may appear surprising, they mirror
some uncertainties of the literature results. Two meta-
analyses [5, 6] analyzed the comparisons of RFA versus PEI
and found a signiﬁcant survival improvement favouring the
former over the latter one, while a systematic review on the
same trials concluded that data does not provide enough
evidence to support survival beneﬁts coming from RFA [24].
The ﬁve randomized trials that tested the two percutaneous
treatments and were considered in the meta-analyses [5, 6]
were small and had a short follow-up. Interestingly, we did
notﬁndanydiﬀerencebetweenRFAandPEIeveninthesub-
groups of patients (like those with larger tumor size) in
which international guidelines claim that RFA should be
more eﬀective than PEI [2].
Surgery has been compared to percutaneous ablation in
three small randomized trials [25–27]. Huang et al. [25]
and Chen et al. [26] did not ﬁnd signiﬁcant beneﬁts of
surgery, while Huang et al. [27] found that surgical resection
increased overall survival in patients who met the Milan cri-
teria. A meta-analysis [4] that included only one randomiz-
ed trial and several observational studies, found a survival
b e n e ﬁ to fs u r g e r yv e r s u sa b l a t i v et r e a t m e n t si nt h es u b g r o u p
of tumors >3cm, but concluded that level of evidence was
low and that further RCT were needed to deﬁne the relative
value of surgery and RFA. Unfortunately in our study the
number of surgical resections, that were performed only in
two big Institutions, is small and comparison is underpower-
ed. However we did not ﬁnd any diﬀerence even in the sub-
groups of patients with single nodules or Child-Pugh A, that
is, the best candidates to resection [2].
To our knowledge TACE/TAE alone have never been
compared with other locoregional treatments since guide-
lines consider TACE/TAE as restricted to ‘nonsurgical HCC
that are also ineligible for percutaneous ablation [2]. As
expected, we found slightly worse patients in the TACE/TAE
group, but in multivariable analysis we were unable to ﬁnd
any diﬀerence in long-term survival from RFA/PEI, neither
overall nor in selected subgroups.
In conclusion, although our approach does not allow
deﬁnitive statements, our results show that, in a real-world
setting, uncertainties in the choice and in the outcome of
local treatments of HCC are still present. Educational pro-
jects and population-based observational studies, supported
by well-planned RCTs, are still needed to deﬁne the relative
eﬀectiveness of locoregional treatments.
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